ALSMA Stock Overview
Provides software, implantable devices, and associated services to treat spinal pathologies requiring surgery. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
S.M.A.I.O S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.45 |
| 52 Week High | €4.34 |
| 52 Week Low | €2.28 |
| Beta | 0.61 |
| 11 Month Change | -27.51% |
| 3 Month Change | -39.66% |
| 1 Year Change | 2.94% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -56.01% |
Recent News & Updates
Shareholder Returns
| ALSMA | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | -4.7% | 2.7% | -0.3% |
| 1Y | 2.9% | 26.7% | -3.5% |
Return vs Industry: ALSMA underperformed the French Medical Equipment industry which returned 28.4% over the past year.
Return vs Market: ALSMA exceeded the French Market which returned -2.5% over the past year.
Price Volatility
| ALSMA volatility | |
|---|---|
| ALSMA Average Weekly Movement | 5.4% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALSMA has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: ALSMA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 43 | Philippe Roussouly | smaio.com |
S.M.A.I.O S.A. provides software, implantable devices, and associated services to treat spinal pathologies requiring surgery. The company was incorporated in 2009 and is based in Saint-Priest, France.
S.M.A.I.O S.A. Fundamentals Summary
| ALSMA fundamental statistics | |
|---|---|
| Market cap | €13.25m |
| Earnings (TTM) | -€1.24m |
| Revenue (TTM) | €6.80m |
1.9x
P/S Ratio-10.3x
P/E RatioIs ALSMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALSMA income statement (TTM) | |
|---|---|
| Revenue | €6.80m |
| Cost of Revenue | €3.51m |
| Gross Profit | €3.28m |
| Other Expenses | €4.52m |
| Earnings | -€1.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Apr 15, 2025
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 48.29% |
| Net Profit Margin | -18.28% |
| Debt/Equity Ratio | 34.0% |
How did ALSMA perform over the long term?
See historical performance and comparison